Kintegral Advisory LLC Has $726,000 Position in ResMed Inc. (NYSE:RMD)

Kintegral Advisory LLC trimmed its position in shares of ResMed Inc. (NYSE:RMD) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,173 shares of the medical equipment provider’s stock after selling 148 shares during the quarter. Kintegral Advisory LLC’s holdings in ResMed were worth $726,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in ResMed by 359.4% during the 3rd quarter. Blue Trust Inc. now owns 974 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 762 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in shares of ResMed by 24,311.9% during the third quarter. International Assets Investment Management LLC now owns 26,609 shares of the medical equipment provider’s stock worth $6,496,000 after purchasing an additional 26,500 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of ResMed by 46.0% in the third quarter. Assenagon Asset Management S.A. now owns 48,931 shares of the medical equipment provider’s stock worth $11,945,000 after purchasing an additional 15,424 shares during the last quarter. Silver Oak Securities Incorporated increased its holdings in ResMed by 5,585.9% in the third quarter. Silver Oak Securities Incorporated now owns 4,833 shares of the medical equipment provider’s stock valued at $1,155,000 after purchasing an additional 4,748 shares during the period. Finally, Outlook Wealth Advisors LLC raised its position in ResMed by 2.8% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 3,686 shares of the medical equipment provider’s stock worth $900,000 after purchasing an additional 102 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares of the company’s stock, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael J. Farrell sold 8,009 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the sale, the chief executive officer now owns 455,472 shares in the company, valued at $107,842,105.44. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,147 shares of company stock worth $2,905,745. Insiders own 0.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stifel Nicolaus started coverage on ResMed in a research report on Friday, December 13th. They issued a “hold” rating and a $250.00 price target on the stock. UBS Group upgraded ResMed from a “hold” rating to a “strong-buy” rating in a report on Friday, January 31st. The Goldman Sachs Group started coverage on shares of ResMed in a report on Thursday, January 16th. They set a “buy” rating for the company. KeyCorp upped their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Piper Sandler lifted their target price on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Price Performance

Shares of NYSE RMD opened at $231.61 on Friday. The firm has a market capitalization of $34.02 billion, a P/E ratio of 27.34, a P/E/G ratio of 1.53 and a beta of 0.70. The firm’s 50-day moving average price is $237.43 and its 200-day moving average price is $239.22. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 1-year low of $170.56 and a 1-year high of $263.05.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Equities research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.92%. ResMed’s dividend payout ratio (DPR) is presently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.